CAJ | 학술논문

目的：探讨添加脑栓通胶囊治疗阿司匹林抵抗的急性脑梗死患者的临床价值。方法将94例有阿司匹林抵抗现象的急性脑梗死患者分为对照组（45例）与观察组（49例），对照组患者仅接受常规治疗，观察组患者在对照组治疗基础上添加使用脑栓通12周，在治疗结束后对比分析两组患者的血小板聚集率及临床疗效。结果①治疗前两组患者血小板聚集率相比差异无统计学意义（P＞0.05）；治疗12周后，观察组血小板聚集率显著低于对照组（P＜0.05）。②治疗前，两组患者NHISS评分、BI评分相比差异无统计学意义（P＞0.05）。治疗12周后，观察组NHISS评分显著低于对照组（P＜0.05），BI评分显著高于对照组（P＜0.05）。③观察组观察期内复发率显著低于对照组（P＜0.05），两组患者脑出血发生率差异无统计学意义（P＞0.05）。结论脑栓通添加治疗可改善急性脑梗死患者的阿司匹林抵抗现象，降低血小板聚集率，同时改善患者临床预后和降低疾病复发率。
목적：탐토첨가뇌전통효낭치료아사필림저항적급성뇌경사환자적림상개치。방법장94례유아사필림저항현상적급성뇌경사환자분위대조조（45례）여관찰조（49례），대조조환자부접수상규치료，관찰조환자재대조조치료기출상첨가사용뇌전통12주，재치료결속후대비분석량조환자적혈소판취집솔급림상료효。결과①치료전량조환자혈소판취집솔상비차이무통계학의의（P＞0.05）；치료12주후，관찰조혈소판취집솔현저저우대조조（P＜0.05）。②치료전，량조환자NHISS평분、BI평분상비차이무통계학의의（P＞0.05）。치료12주후，관찰조NHISS평분현저저우대조조（P＜0.05），BI평분현저고우대조조（P＜0.05）。③관찰조관찰기내복발솔현저저우대조조（P＜0.05），량조환자뇌출혈발생솔차이무통계학의의（P＞0.05）。결론뇌전통첨가치료가개선급성뇌경사환자적아사필림저항현상，강저혈소판취집솔，동시개선환자림상예후화강저질병복발솔。
Objective Explore clinical value of naoshuantong treatment in patients who are aspirin resistance with cerebral infarction. Methods 94 patients were divided into control group (45 cases) and observation group (49 cases), control group patients received only conventional therapy, observation group of patients based on the control group treatment and combined use naoshuantong 12 weeks. At the end of the treatment, comparative analysis of two groups of patients. Result ①before the treatment, the platelet aggregation rate two groups of patients was no statistically signiifcant difference (P>0.05), after 12 weeks treatment, the observation platelet aggregation rate was signiifcantly lower than the control group (P<0.05).②before the treatment, two groups of patients, NHISS score compared with BI score was no statistically signiifcant difference (P>0.05). 12 weeks after treatment, the observation group NHISS score was signiifcantly lower than the control group (P<0.05), BI score was signiifcantly higher than the control group (P<0.05).③Observation group follow-up recurrence rate was signiifcantly lower than the control group (P<0.05). Conclusion Naoshuantong treatment in patients with cerebral infarction can reduce aspirin resistance and platelet aggregation rate, improve clinical prognosis and decrease recurrence rate.